Dzik WH.Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. J Intensive Care Med. 2006; 21:1-6.
2.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J.Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988; 19:604-607.
3.
Wilson JT, Pettigrew LE, Teasdale GM.Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998; 15:573-585.
4.
Mahoney FI, Barthel DW.Functional evaluation: the Barthel index. Md State Med J. 1965; 14:61-65.
5.
Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G.Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993; 24:987-993.
6.
Brott T, Broderick J, Kothari R, et al.Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997; 28:1-5.
7.
Mayer SA, Brun MC, Begtrup K, et al.Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005; 352:777-785.
